ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc (ENTA)

11,19
0,12
( 1,08% )
Aktualisiert: 19:32:47

Enanta Pharmaceuticals Inc (ENTA) Aktie

Professionelle Tools für Privatanleger.

Premium

Wichtige Statistiken und Details

Current Price
11,19
( 1,08% )
Gebot
11,25
Fragen
11,30
Volumen
55.188
11,185 Tagesbereich 11,55
6,435 52-Wochen-Bereich 17,15
Marktkapitalisierung
Handelsende
11,07
Handelsbeginn
11,23
Letzte Trade
30
@
11.27
Letzter Handelszeitpunkt
19:34:45
Finanzvolumen
US$ 622.057
VWAP
11,2716
Durchschnittliches Volumen (3 Mio.)
US$ 169.589
Ausgegebene Aktien
29.078.380
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-4,57
Gewinn pro Aktie (EPS)
-2,47
Erlöse (LTM)
69,21M
Nettogewinn (LTM)
-61,98M

Über Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV... Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Website
Hauptsitz
Watertown, United States
Gegründet
1995
Enanta Pharmaceuticals Inc is listed in the Healthcare sector of the NASDAQ with ticker ENTA. The last closing price for Enanta Pharmaceuticals was US$11,07. Over the last year, Enanta Pharmaceuticals shares have traded in a share price range of US$ 6,435 to US$ 17,15.

Enanta Pharmaceuticals currently has 29.078.380 shares in issue. The market capitalisation of Enanta Pharmaceuticals is US$325,39 million. Enanta Pharmaceuticals has a price to earnings ratio (PE ratio) of -4.57.

ENTA Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-1.32-10.55155875312.5113.23510.8621421711.46067513CS
4-3.405-23.329907502614.59515.3810.8621968613.05797002CS
12-2.33-17.233727810713.5215.9310.8616498913.48385487CS
26-2.88-20.469083155714.0717.1510.8620555513.91666287CS
523.6348.01587301597.5617.156.43533249212.24907404CS
156-15.01-57.290076335926.226.914.0930206511.26142634CS
260-37.53-77.032019704448.721024.0926158024.59975322CS

ENTA - Frequently Asked Questions (FAQ)

What is the current Enanta Pharmaceuticals Inc share price?
The current share price of Enanta Pharmaceuticals Inc is US$ 11,19
How many Enanta Pharmaceuticals Inc shares are in issue?
Enanta Pharmaceuticals Inc has 29.078.380 shares in issue
What is the market cap of Enanta Pharmaceuticals Inc?
The market capitalisation of Enanta Pharmaceuticals Inc is USD 325,39M
What is the 1 year trading range for Enanta Pharmaceuticals Inc share price?
Enanta Pharmaceuticals Inc has traded in the range of US$ 6,435 to US$ 17,15 during the past year
What is the PE ratio of Enanta Pharmaceuticals Inc?
The price to earnings ratio of Enanta Pharmaceuticals Inc is -4,57
What is the cash to sales ratio of Enanta Pharmaceuticals Inc?
The cash to sales ratio of Enanta Pharmaceuticals Inc is 4,74
What is the registered address of Enanta Pharmaceuticals Inc?
The registered address for Enanta Pharmaceuticals Inc is 4 Kingsbury Avenue, Watertown, Massachusetts, 02472
What is the Enanta Pharmaceuticals Inc website address?
The website address for Enanta Pharmaceuticals Inc is www.enanta.com
Which industry sector does Enanta Pharmaceuticals Inc operate in?
Enanta Pharmaceuticals Inc operates in the Biotechnology & Life Sciences sector

ENTA Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen